New HIV data, released today by the Kirby Institute at UNSW Sydney for World AIDS Day, are a reminder for Australia to sustain its efforts in HIV prevention amidst the COVID-19 pandemic.
A global-first, UNSW-led trial of an HIV prevention medication has resulted in an almost one-third decline in infections in the large-scale target group.
An increase in condomless sex in pre-exposure prophylaxis users is predictable as preventing HIV is the key motivator for condom use among gay and bisexual men.
Infectious diseases expert Clifford Lane will deliver UNSW Medicine's Dean's Lecture, outlining the challenges ahead to find a cure for the close to 40 million people living with HIV/AIDS.
Starting HIV treatment early, before immune damage occurs, brings real clinical benefits. But taking antiretrovirals is a daily, life-long commitment and people need support to make the right choices, writes Bridget Haire.
An international study led by UNSW’s Kirby Institute has shown immediate treatment for people who are HIV positive can halve their risk of HIV-related serious disease or death.
Annual HIV funding from developed to developing countries is about $US18 billion, however this is still about $US5 billion a year short of what’s required to sustain the gains of the last decade, writes William Bowtell.
Two men treated at St Vincent’s Hospital in partnership with UNSW's Kirby Institute have undetectable levels of HIV more than three years after their bone marrow transplants, the first successful cases of the HIV virus being cleared in Australia.
Australia has long been seen as a world leader in HIV prevention, treatment and care, yet our academic sector has been underutilised when it comes to the delivery of international health aid, write David Cooper and John Kaldor.
